[{"id":"43ad41ea-ee88-438e-ba85-a91a571ee263","acronym":"","url":"https://clinicaltrials.gov/study/NCT03996239","created_at":"2022-01-29T17:44:32.508Z","updated_at":"2024-07-02T16:34:25.688Z","phase":"","brief_title":"Researching the Effect of Aerobic Exercise on Cancer","source_id_and_acronym":"NCT03996239","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-14"},{"id":"ef502e78-36b6-4881-b791-586dbda2fa9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379999","created_at":"2021-01-18T21:09:15.617Z","updated_at":"2024-07-02T16:34:26.352Z","phase":"Phase 1","brief_title":"Atorvastatin ± Aspirin in Lynch Syndrome Syndrome","source_id_and_acronym":"NCT04379999","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM • CASP3","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"28c966c6-aa0a-48ec-89d0-5286ecccf723","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912559","created_at":"2021-01-18T14:17:52.733Z","updated_at":"2024-07-02T16:34:37.129Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","source_id_and_acronym":"NCT02912559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • CD4","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation • MSH6 expression","tags":["MLH1 • MSH6 • MSH2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2024-06-07"},{"id":"99825282-13d0-4537-9611-5aeeb9d9b074","acronym":"PCEDP","url":"https://clinicaltrials.gov/study/NCT02206360","created_at":"2021-01-18T10:19:50.126Z","updated_at":"2024-07-02T16:35:01.200Z","phase":"","brief_title":"Pancreatic Cancer Early Detection Program","source_id_and_acronym":"NCT02206360 - PCEDP","lead_sponsor":"White Plains Hospital","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-24"},{"id":"49b179a4-49c2-42ed-89ad-455bd2fc9469","acronym":"","url":"https://clinicaltrials.gov/study/NCT04019964","created_at":"2021-01-18T19:44:07.317Z","updated_at":"2024-07-02T16:35:07.439Z","phase":"Phase 2","brief_title":"Nivolumab in Biochemically Recurrent dMMR Prostate Cancer","source_id_and_acronym":"NCT04019964","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" TMB • MSI • MLH1 • MSH6 • MSH2 • CDK12","pipe":" | ","alterations":" MSI-H/dMMR • CDK12 mutation • MSH2 mutation • MLH1 mutation","tags":["TMB • MSI • MLH1 • MSH6 • MSH2 • CDK12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • CDK12 mutation • MSH2 mutation • MLH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/13/2020","start_date":" 01/13/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-26"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"668fd5a3-2595-4b5e-9008-d986e7e3501e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05078866","created_at":"2021-10-15T15:53:08.571Z","updated_at":"2024-07-02T16:35:09.625Z","phase":"Phase 1/2","brief_title":"Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients","source_id_and_acronym":"NCT05078866","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRAF mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOUS-209"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/10/2022","start_date":" 11/10/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-04-15"},{"id":"107dd190-b738-4816-b39c-d6828e427b79","acronym":"PancreasScan","url":"https://clinicaltrials.gov/study/NCT05006131","created_at":"2021-08-16T17:54:43.106Z","updated_at":"2024-07-02T16:35:13.981Z","phase":"","brief_title":"Pancreatic Cancer Screening for At-risk Individuals","source_id_and_acronym":"NCT05006131 - PancreasScan","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 03/10/2027","primary_completion_date":" 03/10/2027","study_txt":" Completion: 03/10/2028","study_completion_date":" 03/10/2028","last_update_posted":"2024-03-19"},{"id":"bc0ab9aa-dfd0-4ac8-8031-f30fc9f954e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411718","created_at":"2022-06-09T13:55:29.609Z","updated_at":"2024-07-02T16:35:15.093Z","phase":"Phase 2","brief_title":"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","source_id_and_acronym":"NCT05411718","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-13"},{"id":"07c7a5d9-df0c-45c5-9b74-abae8c8d1379","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751761","created_at":"2021-01-18T18:23:38.922Z","updated_at":"2024-07-02T16:35:17.456Z","phase":"Phase 1/2","brief_title":"GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study","source_id_and_acronym":"NCT03751761","lead_sponsor":"Asan Medical Center","biomarkers":" PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation","tags":["PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 06/11/2018","start_date":" 06/11/2018","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2024-02-28"},{"id":"b53740c4-b1e7-41cb-af68-382331f382df","acronym":"","url":"https://clinicaltrials.gov/study/NCT06206083","created_at":"2024-01-16T20:20:19.657Z","updated_at":"2024-07-02T16:35:17.516Z","phase":"","brief_title":"Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis","source_id_and_acronym":"NCT06206083","lead_sponsor":"National Institute of Cancerología","biomarkers":" TP53 • MSI • POLE • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" POLE mutation • MLH1 mutation","tags":["TP53 • MSI • POLE • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation • MLH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-02-28"},{"id":"f4760edc-575b-4a03-b52a-92d92e44dfde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02371135","created_at":"2021-01-18T11:17:42.064Z","updated_at":"2024-07-02T16:35:21.010Z","phase":"","brief_title":"Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes","source_id_and_acronym":"NCT02371135","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-02"},{"id":"bfb4df12-9ec3-4d7d-b560-7b4ce0e231e4","acronym":"CORAL","url":"https://clinicaltrials.gov/study/NCT05410977","created_at":"2022-06-08T11:58:19.127Z","updated_at":"2024-07-02T16:35:23.099Z","phase":"","brief_title":"Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study","source_id_and_acronym":"NCT05410977 - CORAL","lead_sponsor":"Mayo Clinic","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 03/30/2022","start_date":" 03/30/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-18"},{"id":"87a9c1fe-92c6-4692-b3ba-4b7c76aefe9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02993068","created_at":"2021-01-18T14:43:23.226Z","updated_at":"2024-07-02T16:35:23.256Z","phase":"","brief_title":"Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)","source_id_and_acronym":"NCT02993068","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation • BRIP1 mutation • MSH2 mutation • RAD51C mutation • MLH1 mutation • RAD51D mutation • PMS2 mutation • BARD1 mutation • RAD51 mutation","tags":["ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation • BRIP1 mutation • MSH2 mutation • RAD51C mutation • MLH1 mutation • RAD51D mutation • PMS2 mutation • BARD1 mutation • RAD51 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 5200","initiation":"Initiation: 04/18/2017","start_date":" 04/18/2017","primary_txt":" Primary completion: 04/18/2024","primary_completion_date":" 04/18/2024","study_txt":" Completion: 04/18/2024","study_completion_date":" 04/18/2024","last_update_posted":"2024-01-17"},{"id":"30822141-25e9-4fd4-a1b7-75e0617cd56c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03495674","created_at":"2021-01-18T17:12:44.870Z","updated_at":"2024-07-02T16:35:24.381Z","phase":"","brief_title":"Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome","source_id_and_acronym":"NCT03495674","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 04/04/2018","start_date":" 04/04/2018","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 01/02/2024","study_completion_date":" 01/02/2024","last_update_posted":"2024-01-05"},{"id":"fc21c219-c013-4138-9fe8-07a9c22cead0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013216","created_at":"2021-08-19T14:52:56.438Z","updated_at":"2024-07-02T16:35:38.156Z","phase":"Phase 1","brief_title":"Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer","source_id_and_acronym":"NCT05013216","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1","pipe":" | ","alterations":" KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation","tags":["KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-04"},{"id":"30d80eb1-2510-4649-9119-db4070bc1354","acronym":"CADLYNCH","url":"https://clinicaltrials.gov/study/NCT05963191","created_at":"2023-07-27T17:08:57.566Z","updated_at":"2024-07-02T16:35:41.858Z","phase":"","brief_title":"CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome","source_id_and_acronym":"NCT05963191 - CADLYNCH","lead_sponsor":"PERROD Guillaume","biomarkers":" MSH2","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2023-07-27"},{"id":"66ad1e5b-f099-4a22-b1d4-f866d0e6058a","acronym":"IMANOL","url":"https://clinicaltrials.gov/study/NCT03434158","created_at":"2021-01-18T16:56:23.710Z","updated_at":"2024-07-02T16:36:01.131Z","phase":"Phase 2","brief_title":"Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)","source_id_and_acronym":"NCT03434158 - IMANOL","lead_sponsor":"Spanish Oncology Genito-Urinary Group","biomarkers":" BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CHEK2 • RAD51C","pipe":" | ","alterations":" CHEK2 mutation • MLH1 mutation","tags":["BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CHEK2 • RAD51C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHEK2 mutation • MLH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • docetaxel"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/06/2018","start_date":" 02/06/2018","primary_txt":" Primary completion: 05/12/2022","primary_completion_date":" 05/12/2022","study_txt":" Completion: 05/12/2022","study_completion_date":" 05/12/2022","last_update_posted":"2022-11-03"},{"id":"b9edba5c-97ab-48e7-9714-b3ab8951ab79","acronym":"MesaCAPP","url":"https://clinicaltrials.gov/study/NCT04920149","created_at":"2021-06-10T01:52:40.134Z","updated_at":"2024-07-02T16:36:14.592Z","phase":"Phase 2","brief_title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","source_id_and_acronym":"NCT04920149 - MesaCAPP","lead_sponsor":"Ann-Sofie Backman","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 10/15/2028","primary_completion_date":" 10/15/2028","study_txt":" Completion: 10/15/2038","study_completion_date":" 10/15/2038","last_update_posted":"2022-03-28"},{"id":"1e164106-e933-418b-8ee7-e87082235b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05131243","created_at":"2021-11-23T13:53:33.533Z","updated_at":"2024-07-02T16:36:20.346Z","phase":"","brief_title":"the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer","source_id_and_acronym":"NCT05131243","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation • MLH3 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation • MLH3 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2021-11-23"},{"id":"7380c081-f953-4211-9a39-e1cfa850f878","acronym":"","url":"https://clinicaltrials.gov/study/NCT02052908","created_at":"2021-03-25T17:20:15.004Z","updated_at":"2024-07-02T16:36:35.655Z","phase":"Phase 1","brief_title":"Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome","source_id_and_acronym":"NCT02052908","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MLH1 mutation • PMS2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 01/27/2014","start_date":" 01/27/2014","primary_txt":" Primary completion: 10/25/2019","primary_completion_date":" 10/25/2019","study_txt":" Completion: 01/05/2021","study_completion_date":" 01/05/2021","last_update_posted":"2021-01-25"},{"id":"7dddf5e6-dc5f-4b14-b406-1a567f4377e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03631641","created_at":"2021-01-18T17:50:12.327Z","updated_at":"2024-07-02T16:36:44.995Z","phase":"Phase 2","brief_title":"Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy","source_id_and_acronym":"NCT03631641","lead_sponsor":"Joanne Jeter","biomarkers":" MLH1 • MSH2","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation","tags":["MLH1 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 3","initiation":"Initiation: 08/21/2018","start_date":" 08/21/2018","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2020-05-15"},{"id":"3ce0329b-2881-44da-aa28-7cd3d5304e86","acronym":"","url":"https://clinicaltrials.gov/study/NCT02048735","created_at":"2021-01-18T09:24:49.775Z","updated_at":"2024-07-02T16:37:15.587Z","phase":"Phase 1","brief_title":"Naproxen for Lynch Syndrome","source_id_and_acronym":"NCT02048735","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-12"},{"id":"7f011359-941f-464e-b15d-667c3ecb1afd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02053805","created_at":"2021-01-18T09:26:41.565Z","updated_at":"2024-07-02T16:37:17.052Z","phase":"","brief_title":"Prostate Cancer Screening Among Men With High Risk Genetic Predisposition","source_id_and_acronym":"NCT02053805","lead_sponsor":"Rabin Medical Center","biomarkers":" BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BRCA mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2017-10-17"}]